These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats. Cai H; Zhou L; Liu J; Li Z; Chen S Biochem Biophys Res Commun; 2022 Nov; 629():112-120. PubMed ID: 36116373 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy. Roumane A; Mcilroy GD; Sommer N; Han W; Heisler LK; Rochford JJ Front Endocrinol (Lausanne); 2024; 15():1379228. PubMed ID: 38745956 [TBL] [Abstract][Full Text] [Related]
6. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates. Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884 [TBL] [Abstract][Full Text] [Related]
7. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Moffett RC; Patterson S; Irwin N; Flatt PR Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010 [TBL] [Abstract][Full Text] [Related]
8. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653 [TBL] [Abstract][Full Text] [Related]
9. Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study. Le Page LM; Rider OJ; Lewis AJ; Ball V; Clarke K; Johansson E; Carr CA; Heather LC; Tyler DJ Diabetes; 2015 Aug; 64(8):2735-43. PubMed ID: 25795215 [TBL] [Abstract][Full Text] [Related]
10. Liraglutide alleviates cardiac fibrosis through inhibiting P4hα-1 expression in STZ-induced diabetic cardiomyopathy. Zhao T; Chen H; Xu F; Wang J; Liu Y; Xing X; Guo L; Zhang M; Lu Q Acta Biochim Biophys Sin (Shanghai); 2019 Mar; 51(3):293-300. PubMed ID: 30883649 [TBL] [Abstract][Full Text] [Related]
11. Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. Trang NN; Chung CC; Lee TW; Cheng WL; Kao YH; Huang SY; Lee TI; Chen YJ Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503985 [TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats. Filchenko I; Simanenkova A; Chefu S; Kolpakova M; Vlasov T Diab Vasc Dis Res; 2018 Nov; 15(6):567-570. PubMed ID: 30024276 [TBL] [Abstract][Full Text] [Related]
13. GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Inoue T; Inoguchi T; Sonoda N; Hendarto H; Makimura H; Sasaki S; Yokomizo H; Fujimura Y; Miura D; Takayanagi R Atherosclerosis; 2015 May; 240(1):250-9. PubMed ID: 25818251 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism. Al Batran R; Almutairi M; Ussher JR Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838 [TBL] [Abstract][Full Text] [Related]
15. Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Helmstädter J; Frenis K; Filippou K; Grill A; Dib M; Kalinovic S; Pawelke F; Kus K; Kröller-Schön S; Oelze M; Chlopicki S; Schuppan D; Wenzel P; Ruf W; Drucker DJ; Münzel T; Daiber A; Steven S Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):145-158. PubMed ID: 31747801 [TBL] [Abstract][Full Text] [Related]
19. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Wang L; Li P; Tang Z; Yan X; Feng B Sci Rep; 2016 Sep; 6():33251. PubMed ID: 27633081 [TBL] [Abstract][Full Text] [Related]
20. Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression. Ramadan NM; Malek HA; Rahman KA; El-Kholy E; Shaalan D; Elkashef W Exp Clin Endocrinol Diabetes; 2021 Dec; 129(12):899-907. PubMed ID: 32559789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]